The development and manufacturing of a cell therapy product is very complicated. There are a lot of materials required to produce the cell therapy product, ranging from cells, plasmids, medias and viral vectors. The quality and reproducibility of the viral vector is critical in the production of a cell therapy product. The properties of the vector should be characterized to ensure an understanding on how the vector can impact the production process and possibly the cell therapy product. The timeline to produce the viral vector needs to be closely integrated with the timeline of the cell therapy development and production. The potential impact the viral vector can have on the cell therapy product potency needs to be characterized and linked to pre-clinical and clinical trial design.

The CHA Medical Group is a fully integrated Healthcare Group with a separate cell therapy business unit. As Matica Biotechnology is part of the larger CHA Medical Group we understand the need to ensure a reliable supply of viral vector for the cell therapy process. Our company has been designed to allow for open access to our viral vector development and manufacturing expertise. We focus on ensuring that your CMC program is provided the correct level of guidance and support to ensure success of the cell therapy program.